出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年6月
ウイルスベクターおよびプラスミドDNA製造市場 : タイプ [ウイルスベクター (レトロウイルス、アデノウイルス、AAV、レンチウイルス)、プラスミド DNA]、ワークフロー (上流、下流)、用途 (細胞、遺伝子治療)、疾患 (がん)、エンドユーザー – 2028年までの世界予測
Viral Vector & Plasmid DNA Manufacturing Market by Type (Viral Vector (Retroviruses, Adenoviruses, AAV, Lentiviruses), Plasmid DNA), Workflow (Upstream, Downstream), Application (Cell & Gene Therapy), Diseases (Cancer), End User – Global Forecast to 2028
| ページ数 | 317 |
| 図表数 | 413 |
| 種別 | 英文調査報告書 |
| 価格 |
The global viral vector and plasmid DNA manufacturing market is projected to reach USD 12.8 billion by 2028 from USD 5.5 billion in 2023, at a CAGR of 18.2% during the forecast period of 2023 to 2028. The growth of this market can be attributed to the availability of funding for the development of gene therapy. Gene therapy is a rapidly growing field, and funding is needed for research and development, clinical trials, and manufacturing. For instance, in December 2022, SonoThera, a biotechnology company announced completion of its USD 60.75 million Series A financing round. The financing will support the continued development of SonoThera’s ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines.
“The vector amplification, editing and expansion segment accounted for the largest share by upstream manufacturing process during the forecast period”
In 2022, vector amplification, editing and expansion segment accounted for the largest share by upstream manufacturing process in the global viral vector and plasmid DNA manufacturing market. Vector amplification, editing, and expansion are critical steps in viral vector and plasmid DNA manufacturing as they directly impact the quantity, quality, and functionality of the vectors. The pharmaceutical and biopharmaceutical industry is witnessing significant advancements, particularly in the development of novel therapeutics and vaccines. Viral vectors and plasmid DNA are crucial tools for delivering therapeutic genes or vaccine antigens. The demand for vector amplification, editing, and expansion is driven by the need to produce a diverse range of viral vectors and plasmid DNA for various therapeutic and vaccine candidates.
“Europe: The second largest region in the viral vector and plasmid DNA manufacturing market”
Europe accounted for the second-largest market for viral vector and plasmid DNA manufacturing market after North America. The European viral vector and plasmid DNA manufacturing market has witnessed significant growth in recent years, driven by various factors that have propelled its expansion. Europe is at the forefront of developing and adopting emerging technologies in the field of viral vector and plasmid DNA manufacturing market. This includes advancements in viral vector and plasmid DNA manufacturing gtechnologies. The adoption of these innovative technologies accelerates the progress of viral vector and plasmid DNA manufacturing research and expands its applications. Additionally, Europe offers comprehensive training and education programs in viral vector and plasmid DNA manufacturing. Universities, research institutes, and organizations provide funding, and conferences to enhance the knowledge and skills of scientists and researchers. The availability of funding promotes the adoption and utilization of of viral vector and plasmid DNA manufacturing technologies in Europe.
The primary interviews conducted for this report can be categorized as follows:
• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: C-level – 45%, D-level – 30%, and Others – 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East & Africa- 5%
List of Companies Profiled in the Report:
• Lonza Group (Switzerland)
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Oxford Biomedica (UK)
• FUJIFILM Corporation (Japan)
• Charles River Laboratories International, Inc. (US)
• Danaher Corporation (US)
• Genscript Biotech Corporation (US)
• SIRION BIOTECH (Germany)
• Catalent, Inc (US)
• Novartis AG (Switzerland)
• Precision Biosciences (US)
• Takara Bio Inc. (japan)
• Bluebird Bio, Inc. (US)
• Sartorius AG (Germany)
• VGXI, INC. (US)
• Waisman Biomanufacturing (US)
• Kaneka Eurogentec S.A. (Belgium)
• PlasmidFactory GmbH (Germany)
• WuXi AppTec (China)
• Atum (US)
• Addgene (US)
• Cell and Gene Therapy Catapult (US)
• Batavia Biosciences B.V. (Netherlands)
• Altogen Biosystems (US)
Research Coverage:
This report provides a detailed picture of the viral vector and plasmid DNA manufacturing market. It aims at estimating the size and future growth potential of the market across different segments such as the type, product & service, workflow, application, disease indication, end user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges
The report provides insights on the following pointers:
• Analysis of key drivers (rising prevalence of genetic disorders, cancer, and infectious diseases, availability of funding for the development of gene therapy, effectiveness of viral vectors and ongoing research into viral vector-based gene and cell therapies), restraints (High operational costs associated with cell & gene therapy manufacturing and Short shelf-life of viral vectors), opportunities (Smart capital deployment and planning for scalability, and Leveraging digital to facilitate operational excellence), and challenges (Risk of mutagenesis and other unwanted outcomes, and Individual optimization and low yields hold back downstream processes) influencing the growth of the market.
• Product and Service Development/Innovation: Detailed insights on newly launched products & services, and technological assessment of the viral vector and plasmid DNA manufacturing market
• Market Development: Comprehensive information about lucrative markets – the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the viral vector and plasmid DNA manufacturing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and products and service offerings of leading players like Lonza Group AG (Switzerland), Merck KGaA (Germany), Thermo Fisher Scientific Inc. (US), Charles River Laboratories International, Inc. (US), Catalent Inc. (US), WuXi AppTec (China), FUJIFILM Corporation (Japan), GenScript Biotech Corporation (US), Takara Bio Inc. (Japan), Oxford Biomedica (UK), Novartis AG (Switzerland), Precision Biosciences (US), Bluebird Bio, Inc. (US), Sartorius AG (Germany), Danaher Corporation (US), SIRON Biotech (Germany), VGXI, Inc. (US), Waisman Biomanufacturing (US), Kaneka Eurogentec S.A. (Belgium), PlasmidFactory GmbH (Germany), ATUM (US), Addgene (US), Cell and Gene Therapy Catapult (UK), Batavia biosciences (Netherlands), and Altogen Biosystems (US)., and among others in the market.
目次
1 INTRODUCTION 46
1.1 STUDY OBJECTIVES 46
1.2 MARKET DEFINITION 46
1.2.1 INCLUSIONS AND EXCLUSIONS 47
1.3 MARKET SCOPE 48
FIGURE 1 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET SEGMENTATION 48
1.3.1 YEARS CONSIDERED 49
1.4 CURRENCY CONSIDERED 49
1.5 LIMITATIONS 49
1.6 STAKEHOLDERS 50
1.7 SUMMARY OF CHANGES 50
1.7.1 RECESSION IMPACT 51
2 RESEARCH METHODOLOGY 52
2.1 RESEARCH APPROACH 52
FIGURE 2 RESEARCH DESIGN 52
2.1.1 SECONDARY RESEARCH 53
2.1.2 PRIMARY DATA 53
FIGURE 3 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: BREAKDOWN OF PRIMARIES 54
2.2 MARKET SIZE ESTIMATION 55
FIGURE 4 MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS, 2022 55
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 56
FIGURE 6 ILLUSTRATIVE EXAMPLE OF LONZA GROUP AG: REVENUE SHARE ANALYSIS (2022) 56
2.2.1 INSIGHTS FROM PRIMARIES 58
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 58
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 58
2.3 GROWTH FORECAST 59
FIGURE 9 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: CAGR PROJECTIONS 60
FIGURE 10 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 60
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 61
FIGURE 11 DATA TRIANGULATION METHODOLOGY 61
2.5 RESEARCH ASSUMPTIONS 62
2.6 RISK ANALYSIS 62
2.7 RECESSION IMPACT ANALYSIS 62
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 62
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 63
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 63
3 EXECUTIVE SUMMARY 64
FIGURE 12 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 64
FIGURE 13 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 65
FIGURE 14 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2023 VS. 2028 (USD MILLION) 65
FIGURE 15 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 66
FIGURE 16 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2023 VS. 2028 (USD MILLION) 67
FIGURE 17 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 67
FIGURE 18 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GEOGRAPHICAL SNAPSHOT 68
4 PREMIUM INSIGHTS 70
4.1 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET OVERVIEW 70
FIGURE 19 ONGOING RESEARCH ON VIRAL VECTOR-BASED CELL AND GENE THERAPIES TO DRIVE MARKET 70
4.2 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: NORTH AMERICA, BY PRODUCT & SERVICE AND COUNTRY 71
FIGURE 20 PRODUCTS SEGMENT IN US ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 71
4.3 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 71
FIGURE 21 PRODUCTS SEGMENT TO WITNESS HIGHEST GROWTH RATE DURING FORECAST PERIOD 71
4.4 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET SHARE, BY END USER (2022) 72
FIGURE 22 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 72
4.5 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 72
FIGURE 23 CHINA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD 72
5 MARKET OVERVIEW 73
5.1 INTRODUCTION 73
5.2 MARKET DYNAMICS 73
FIGURE 24 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 73
TABLE 4 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: IMPACT ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 74
5.2.1 DRIVERS 74
5.2.1.1 Rising prevalence of genetic disorders, cancer, and infectious diseases 74
5.2.1.2 Availability of funding for development of gene therapy 75
5.2.1.3 Effectiveness of viral vectors 76
5.2.1.4 Ongoing research on viral vector-based gene and cell therapies 76
TABLE 5 OVERVIEW OF CURRENT CLINICAL TRIALS BASED ON VECTOR TYPE 76
5.2.2 RESTRAINTS 77
5.2.2.1 High operational costs associated with cell and gene therapy manufacturing 77
5.2.2.2 Short shelf life of viral vectors 77
5.2.3 OPPORTUNITIES 78
5.2.3.1 Smart capital deployment and planning for scalability 78
5.2.3.2 Leveraging digital tools to facilitate operational excellence 78
5.2.4 CHALLENGES 79
5.2.4.1 Risk of mutagenesis and other unwanted outcomes 79
5.2.4.2 Individual optimization and low yield 79
5.3 INDICATIVE PRICING ANALYSIS 79
TABLE 6 PRICING ANALYSIS FOR PRODUCTS 80
5.4 VALUE CHAIN ANALYSIS 81
5.5 VALUE CHAIN ANALYSIS: MANUFACTURING PHASES ADD MAXIMUM VALUE 82
5.5.1 ECOSYSTEM ANALYSIS 82
FIGURE 25 ECOSYSTEM ANALYSIS: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET 83
TABLE 7 OVERALL MARKET ECOSYSTEM FOR VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET 84
5.6 PORTER’S FIVE FORCES ANALYSIS 85
TABLE 8 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: PORTER’S FIVE FORCES ANALYSIS 85
5.6.1 THREAT OF NEW ENTRANTS 86
5.6.2 THREAT OF SUBSTITUTES 86
5.6.3 BARGAINING POWER OF BUYERS 86
5.6.4 BARGAINING POWER OF SUPPLIERS 86
5.6.5 INTENSITY OF COMPETITIVE RIVALRY 86
5.7 TECHNOLOGY ANALYSIS 87
TABLE 9 EXAMPLES OF ADVANCED PRODUCTS/PLATFORMS 87
5.8 PATENT ANALYSIS 88
FIGURE 26 TOP PATENT OWNERS IN VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, JANUARY 2014 TO JANUARY 2023 88
TABLE 10 EXAMPLES OF RECENT PATENT ACTIVITY IN VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET 88
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 89
FIGURE 27 REVENUE SHIFT AND NEW REVENUE POCKETS FOR VIRAL VECTOR AND PLASMID DNA MANUFACTURERS 89
5.10 REGULATORY ANALYSIS 90
5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 90
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 91
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 92
TABLE 14 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 93
TABLE 15 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 94
5.11 KEY CONFERENCES AND EVENTS IN 2022–2023 94
TABLE 16 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: LIST OF CONFERENCES AND EVENTS 94
5.12 KEY STAKEHOLDERS AND BUYING CRITERIA 95
5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS 95
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS 96
5.12.2 BUYING CRITERIA FOR VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS AND SERVICES 96
FIGURE 29 KEY BUYING CRITERIA FOR END USERS 97
6 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE 98
6.1 INTRODUCTION 99
TABLE 17 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 99
6.2 VIRAL VECTOR 99
TABLE 18 VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 100
TABLE 19 VIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 100
TABLE 20 NORTH AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 100
TABLE 21 EUROPE: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 22 ASIA PACIFIC: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 23 LATIN AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 101
6.2.1 RETROVIRUS 102
6.2.1.1 Rising application of retroviruses in gene therapy and gene transfer studies to support growth 102
TABLE 24 RETROVIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 25 NORTH AMERICA: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 26 EUROPE: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 27 ASIA PACIFIC: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 28 LATIN AMERICA: RETROVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 104
6.2.2 ADENOVIRUS 104
6.2.2.1 Large capacity for carrying genetic material to promote growth 104
TABLE 29 ADENOVIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 104
TABLE 30 NORTH AMERICA: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 31 EUROPE: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 32 ASIA PACIFIC: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 105
TABLE 33 LATIN AMERICA: ADENOVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106
6.2.3 ADENO-ASSOCIATED VIRUS 106
6.2.3.1 Low toxicity to support demand growth 106
TABLE 34 AAV VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 107
TABLE 35 NORTH AMERICA: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 36 EUROPE: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 107
TABLE 37 ASIA PACIFIC: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 38 LATIN AMERICA: AAV VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
6.2.4 LENTIVIRUS 108
6.2.4.1 Ability to infect both dividing and non-dividing cells to drive growth 108
TABLE 39 LENTIVIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 109
TABLE 40 NORTH AMERICA: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 41 EUROPE: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 42 ASIA PACIFIC: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 43 LATIN AMERICA: LENTIVIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 110
6.2.5 OTHER VIRAL VECTORS 110
TABLE 44 OTHER VIRAL VECTOR MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 45 NORTH AMERICA: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 111
TABLE 46 EUROPE: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 47 ASIA PACIFIC: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 48 LATIN AMERICA: OTHER VIRAL VECTOR MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
6.3 PLASMID DNA 113
6.3.1 GROWING R&D AND LAUNCHES OF PRODUCTION PLATFORMS TO BOOST MARKET 113
TABLE 49 PLASMID DNA MANUFACTURING MARKET, BY REGION 2021–2028 (USD MILLION) 113
TABLE 50 NORTH AMERICA: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 51 EUROPE: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 52 ASIA PACIFIC: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 53 LATIN AMERICA: PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
7 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE 115
7.1 INTRODUCTION 116
TABLE 54 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 116
7.2 PRODUCTS 116
7.2.1 INCREASING PRODUCT LAUNCHES TO DRIVE MARKET GROWTH 116
TABLE 55 VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS, BY KEY PLAYER 117
TABLE 56 VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY REGION, 2021–2028 (USD MILLION) 118
TABLE 57 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 58 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 59 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 60 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING PRODUCTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
7.3 SERVICES 119
7.3.1 INCREASING DEMAND FOR SERVICES TO BOOST MARKET 119
TABLE 61 VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES, BY KEY PLAYER 120
TABLE 62 VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 63 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 64 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 65 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 66 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
8 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW 123
8.1 INTRODUCTION 124
TABLE 67 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 124
8.2 UPSTREAM MANUFACTURING 124
TABLE 68 VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 125
TABLE 69 VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 125
TABLE 70 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 71 EUROPE: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 72 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
TABLE 73 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 126
8.2.1 VECTOR AMPLIFICATION, EDITING, AND EXPANSION 127
8.2.1.1 Increasing demand for gene therapy to fuel growth 127
TABLE 74 VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY REGION, 2021–2028 (USD MILLION) 127
TABLE 75 NORTH AMERICA: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 76 EUROPE: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 77 ASIA PACIFIC: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 78 LATIN AMERICA: VECTOR AMPLIFICATION, EDITING, AND EXPANSION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
8.2.2 VECTOR RECOVERY/HARVESTING 129
8.2.2.1 Rising clinical trials and approvals of cell and gene-based therapies to drive demand for vector recovery/harvesting 129
TABLE 79 VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY REGION, 2021–2028 (USD MILLION) 130
TABLE 80 NORTH AMERICA: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 81 EUROPE: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 82 ASIA PACIFIC: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
TABLE 83 LATIN AMERICA: VECTOR RECOVERY/HARVESTING PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 131
8.3 DOWNSTREAM MANUFACTURING 131
TABLE 84 VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 132
TABLE 85 VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY REGION 2021–2028 (USD MILLION) 132
TABLE 86 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 87 EUROPE: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 88 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 89 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
8.3.1 PURIFICATION 134
8.3.1.1 Technological advancements in purification to drive market 134
TABLE 90 PURIFICATION PROCESSES MARKET, BY REGION, 2021–2028 (USD MILLION) 134
TABLE 91 NORTH AMERICA: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 92 EUROPE: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 93 ASIA PACIFIC: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 94 LATIN AMERICA: PURIFICATION PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
8.3.2 FILL-FINISH 136
8.3.2.1 Technological advancements in downstream manufacturing process 136
TABLE 95 FILL-FINISH PROCESSES MARKET, BY REGION, 2021–2028 (USD MILLION) 136
TABLE 96 NORTH AMERICA: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 97 EUROPE: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 98 ASIA PACIFIC: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 137
TABLE 99 LATIN AMERICA: FILL-FINISH PROCESSES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
9 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION 139
9.1 INTRODUCTION 140
TABLE 100 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140
9.2 CELL & GENE THERAPY 140
9.2.1 ROBUST PIPELINE FOR CELL & GENE THERAPY TO DRIVE MARKET 140
TABLE 101 NUMBER OF CELL AND GENE THERAPIES IN CLINICAL TRIAL PHASES (2021) 141
TABLE 102 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY REGION, 2021–2028 (USD MILLION) 141
TABLE 103 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 141
TABLE 104 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 105 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 142
TABLE 106 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2021–2028 (USD MILLION) 142
9.3 VACCINE DEVELOPMENT 143
9.3.1 DEVELOPMENT OF NOVEL VACCINES TO DRIVE DEMAND FOR VIRAL VECTORS AND PLASMID DNA 143
TABLE 107 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY REGION 2021–2028 (USD MILLION) 143
TABLE 108 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 109 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 110 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 111 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR VACCINE DEVELOPMENT, BY COUNTRY, 2021–2028 (USD MILLION) 145
9.4 RESEARCH 145
9.4.1 RISING R&D TO INTRODUCE NEW APPLICATIONS OF VIRAL VECTOR AND PLASMID DNA 145
TABLE 112 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY REGION 2021–2028 (USD MILLION) 145
TABLE 113 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 114 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 115 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 146
TABLE 116 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR RESEARCH, BY COUNTRY, 2021–2028 (USD MILLION) 147
10 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION 148
10.1 INTRODUCTION 149
TABLE 117 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 149
10.2 CANCER 149
10.2.1 INCREASING PATIENT POPULATION TO PROPEL MARKET GROWTH 149
TABLE 118 NUMBER OF NEW CANCER CASES, BY TYPE, 2020 VS. 2040 150
TABLE 119 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY REGION, 2021–2028 (USD MILLION) 150
TABLE 120 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 121 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 122 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 123 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR CANCER, BY COUNTRY, 2021–2028 (USD MILLION) 152
10.3 GENETIC DISORDERS 152
10.3.1 LAUNCH OF ADVANCED TOOLS TO DELIVER THERAPEUTIC GENES TO SUPPORT MARKET GROWTH 152
TABLE 124 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY REGION, 2021–2028 (USD MILLION) 153
TABLE 125 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 126 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 127 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 128 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR GENETIC DISORDERS, BY COUNTRY, 2021–2028 (USD MILLION) 154
10.4 INFECTIOUS DISEASES 154
10.4.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 154
TABLE 129 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 130 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 155
TABLE 131 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 132 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 133 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 156
10.5 OTHER DISEASE INDICATIONS 157
TABLE 134 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2021–2028 (USD MILLION) 157
TABLE 135 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 136 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 137 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 138 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER DISEASE INDICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 158
11 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER 159
11.1 INTRODUCTION 160
TABLE 139 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 160
11.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES 160
11.2.1 GROWING CELL & GENE THERAPY R&D TO BOOST GROWTH 160
TABLE 140 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION) 161
TABLE 141 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 142 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 143 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 144 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 163
11.3 ACADEMIC & RESEARCH INSTITUTES 163
11.3.1 INCREASING DRUG DISCOVERY RESEARCH PROGRAMS TO DRIVE MARKET 163
TABLE 145 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 164
TABLE 146 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 147 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 148 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 149 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 165
11.4 OTHER END USERS 165
TABLE 150 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 166
TABLE 151 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 166
TABLE 152 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 153 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 154 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 167
12 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION 168
12.1 INTRODUCTION 169
TABLE 155 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY REGION, 2021–2028 (USD MILLION) 169
12.2 NORTH AMERICA 169
12.2.1 NORTH AMERICA: RECESSION IMPACT 170
FIGURE 30 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET SNAPSHOT 171
TABLE 156 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 171
TABLE 157 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 158 NORTH AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 172
TABLE 159 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 172
TABLE 160 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 173
TABLE 161 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 173
TABLE 162 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 173
TABLE 163 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 174
TABLE 164 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 174
TABLE 165 NORTH AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 174
12.2.2 US 175
12.2.2.1 Increasing incidence of cancer to propel market 175
TABLE 166 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 175
TABLE 167 US: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 176
TABLE 168 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 176
TABLE 169 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 176
TABLE 170 US: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 177
TABLE 171 US: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 177
TABLE 172 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 177
TABLE 173 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 178
TABLE 174 US: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 178
12.2.3 CANADA 178
12.2.3.1 Government initiatives to promote research to support market growth 178
TABLE 175 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 176 CANADA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 179
TABLE 177 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 180
TABLE 178 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 180
TABLE 179 CANADA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 180
TABLE 180 CANADA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 181
TABLE 181 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 181
TABLE 182 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 181
TABLE 183 CANADA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 182
12.3 EUROPE 182
12.3.1 EUROPE: RECESSION IMPACT 182
TABLE 184 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 185 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 183
TABLE 186 EUROPE: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 184
TABLE 187 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 184
TABLE 188 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 184
TABLE 189 EUROPE: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 185
TABLE 190 EUROPE: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 185
TABLE 191 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 185
TABLE 192 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 186
TABLE 193 EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 186
12.3.2 GERMANY 186
12.3.2.1 Presence of large number of academic research institutes to propel market 186
TABLE 194 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 195 GERMANY: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 187
TABLE 196 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 188
TABLE 197 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 188
TABLE 198 GERMANY: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 188
TABLE 199 GERMANY: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 189
TABLE 200 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 189
TABLE 201 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 189
TABLE 202 GERMANY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 190
12.3.3 UK 190
12.3.3.1 Increasing R&D investments by pharmaceutical companies to support market 190
TABLE 203 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 204 UK: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 191
TABLE 205 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 191
TABLE 206 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 192
TABLE 207 UK: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 192
TABLE 208 UK: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 192
TABLE 209 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 193
TABLE 210 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 193
TABLE 211 UK: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 193
12.3.4 FRANCE 194
12.3.4.1 Focus on increasing use of generic drugs to drive market 194
TABLE 212 FRANCE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 194
TABLE 213 FRANCE: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 195
TABLE 214 FRANCE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 195
TABLE 215 FRANCE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 195
TABLE 216 FRANCE: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 196
TABLE 217 FRANCE: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 196
TABLE 218 FRANCE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 196
TABLE 219 FRANCE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 197
TABLE 220 FRANCE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 197
12.3.5 ITALY 197
12.3.5.1 Collaborative research initiatives to support market growth 197
TABLE 221 ITALY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 222 ITALY: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 198
TABLE 223 ITALY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 198
TABLE 224 ITALY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 199
TABLE 225 ITALY: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 199
TABLE 226 ITALY: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 199
TABLE 227 ITALY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 200
TABLE 228 ITALY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 200
TABLE 229 ITALY: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 200
12.3.6 SPAIN 201
12.3.6.1 Rising R&D expenditure to boost market growth 201
TABLE 230 SPAIN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 231 SPAIN: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 201
TABLE 232 SPAIN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 202
TABLE 233 SPAIN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 202
TABLE 234 SPAIN: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 202
TABLE 235 SPAIN: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 203
TABLE 236 SPAIN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 203
TABLE 237 SPAIN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 203
TABLE 238 SPAIN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 204
12.3.7 REST OF EUROPE 204
TABLE 239 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 240 REST OF EUROPE: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 205
TABLE 241 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 205
TABLE 242 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 206
TABLE 243 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 206
TABLE 244 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 206
TABLE 245 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 207
TABLE 246 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 207
TABLE 247 REST OF EUROPE: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 207
12.4 ASIA PACIFIC 208
12.4.1 ASIA PACIFIC: RECESSION IMPACT 208
TABLE 248 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 209
TABLE 249 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 209
TABLE 250 ASIA PACIFIC: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 210
TABLE 251 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 210
TABLE 252 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 210
TABLE 253 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 211
TABLE 254 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 211
TABLE 255 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 211
TABLE 256 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 212
TABLE 257 ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 212
12.4.2 CHINA 212
12.4.2.1 Low manufacturing costs and high demand for medicines to drive market 212
TABLE 258 CHINA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 259 CHINA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 213
TABLE 260 CHINA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 214
TABLE 261 CHINA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 214
TABLE 262 CHINA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 214
TABLE 263 CHINA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 215
TABLE 264 CHINA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 215
TABLE 265 CHINA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 215
TABLE 266 CHINA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 216
12.4.3 JAPAN 216
12.4.3.1 Growing geriatric population to support market growth 216
TABLE 267 JAPAN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 268 JAPAN: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 269 JAPAN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 217
TABLE 270 JAPAN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 218
TABLE 271 JAPAN: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 218
TABLE 272 JAPAN: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 218
TABLE 273 JAPAN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 219
TABLE 274 JAPAN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 219
TABLE 275 JAPAN: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 219
12.4.4 INDIA 220
12.4.4.1 Growing pharmaceutical industry to create favorable opportunities for market players 220
TABLE 276 INDIA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 220
TABLE 277 INDIA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 221
TABLE 278 INDIA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 221
TABLE 279 INDIA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 221
TABLE 280 INDIA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 222
TABLE 281 INDIA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 222
TABLE 282 INDIA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 222
TABLE 283 INDIA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 223
TABLE 284 INDIA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 223
12.4.5 SOUTH KOREA 223
12.4.5.1 Strong foundation for development and production of viral vectors to support market growth 223
TABLE 285 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 286 SOUTH KOREA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 287 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 225
TABLE 288 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 225
TABLE 289 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, 2021–2028 (USD MILLION) 225
TABLE 290 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 226
TABLE 291 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 226
TABLE 292 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 226
TABLE 293 SOUTH KOREA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 227
12.4.6 REST OF ASIA PACIFIC 227
TABLE 294 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 295 REST OF ASIA PACIFIC: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 228
TABLE 296 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 228
TABLE 297 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 229
TABLE 298 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 229
TABLE 299 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 229
TABLE 300 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 230
TABLE 301 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 230
TABLE 302 REST OF ASIA PACIFIC: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 230
12.5 LATIN AMERICA 231
12.5.1 LATIN AMERICA: RECESSION IMPACT 231
TABLE 303 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 231
TABLE 304 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 232
TABLE 305 LATIN AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 232
TABLE 306 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 232
TABLE 307 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 233
TABLE 308 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 233
TABLE 309 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 233
TABLE 310 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 234
TABLE 311 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 234
TABLE 312 LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 234
12.5.2 BRAZIL 235
12.5.2.1 Increasing pharmaceutical R&D to drive market 235
TABLE 313 BRAZIL: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 314 BRAZIL: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 235
TABLE 315 BRAZIL: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 236
TABLE 316 BRAZIL: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 236
TABLE 317 BRAZIL: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 236
TABLE 318 BRAZIL: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 237
TABLE 319 BRAZIL: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 237
TABLE 320 BRAZIL: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 237
TABLE 321 BRAZIL: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 238
12.5.3 REST OF LATIN AMERICA 238
TABLE 322 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 238
TABLE 323 REST OF LATIN AMERICA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 239
TABLE 324 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 239
TABLE 325 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 239
TABLE 326 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 240
TABLE 327 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 240
TABLE 328 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 240
TABLE 329 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 241
TABLE 330 REST OF LATIN AMERICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 241
12.6 MIDDLE EAST & AFRICA 241
12.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET 241
12.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 242
TABLE 331 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 332 MIDDLE EAST & AFRICA: VIRAL VECTOR MANUFACTURING MARKET, BY TYPE, 2021–2028 (USD MILLION) 243
TABLE 333 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 243
TABLE 334 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY WORKFLOW, 2021–2028 (USD MILLION) 244
TABLE 335 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA UPSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 244
TABLE 336 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA DOWNSTREAM MANUFACTURING MARKET, BY PROCESS, 2021–2028 (USD MILLION) 244
TABLE 337 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 245
TABLE 338 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY DISEASE INDICATION, 2021–2028 (USD MILLION) 245
TABLE 339 MIDDLE EAST & AFRICA: VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET, BY END USER, 2021–2028 (USD MILLION) 245
13 COMPETITIVE LANDSCAPE 246
13.1 INTRODUCTION 246
13.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 247
FIGURE 31 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS, 2020–2023 247
13.3 MARKET SHARE ANALYSIS 248
FIGURE 32 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 248
TABLE 340 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: DEGREE OF COMPETITION 248
13.4 REVENUE SHARE ANALYSIS 250
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022 250
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS 250
FIGURE 34 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 251
13.5.1 STARS 251
13.5.2 EMERGING LEADERS 251
13.5.3 PERVASIVE PLAYERS 252
13.5.4 PARTICIPANTS 252
13.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 252
13.6.1 PRODUCT & SERVICE FOOTPRINT OF COMPANIES (25 COMPANIES) 252
TABLE 341 PRODUCT & SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET 252
13.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 253
TABLE 342 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET 253
13.7 COMPANY EVALUATION MATRIX: START-UPS/SMES 255
FIGURE 35 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 255
13.7.1 PROGRESSIVE COMPANIES 256
13.7.2 STARTING BLOCKS 256
13.7.3 RESPONSIVE COMPANIES 256
13.7.4 DYNAMIC COMPANIES 256
13.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 257
TABLE 343 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 257
TABLE 344 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 258
13.9 COMPETITIVE SCENARIO AND TRENDS 259
13.9.1 PRODUCT & SERVICE LAUNCHES 259
TABLE 345 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2020–MAY 2023 259
13.9.2 DEALS 260
TABLE 346 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: DEALS, JANUARY 2020–MAY 2023 260
13.9.3 OTHER DEVELOPMENTS 261
TABLE 347 VIRAL VECTOR AND PLASMID DNA MANUFACTURING MARKET: OTHER DEVELOPMENTS, JANUARY 2020–MAY 2023 261
14 COMPANY PROFILES 262
(Business Overview, Products & services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
14.1 KEY COMPANIES 262
14.1.1 LONZA GROUP 262
TABLE 348 LONZA GROUP: BUSINESS OVERVIEW 262
FIGURE 36 LONZA GROUP: COMPANY SNAPSHOT (2022) 263
14.1.2 MERCK KGAA 267
TABLE 349 MERCK KGAA: BUSINESS OVERVIEW 267
FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2022) 268
14.1.3 THERMO FISHER SCIENTIFIC INC. 271
TABLE 350 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 271
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 272
14.1.4 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 276
TABLE 351 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: BUSINESS OVERVIEW 276
FIGURE 39 CHARLES RIVER LABORATORIES INTERNATIONAL, INC.: COMPANY SNAPSHOT (2022) 277
14.1.5 CATALENT, INC. 280
TABLE 352 CATALENT, INC: BUSINESS OVERVIEW 280
FIGURE 40 CATALENT, INC: COMPANY SNAPSHOT (2022) 281
14.1.6 WUXI APPTEC CO., LTD. 284
TABLE 353 WUXI APPTEC CO., LTD.: BUSINESS OVERVIEW 284
FIGURE 41 WUXI APPTEC CO., LTD.: COMPANY SNAPSHOT (2022) 285
14.1.7 FUJIFILM CORPORATION 288
TABLE 354 FUJIFILM CORPORATION: BUSINESS OVERVIEW 288
FIGURE 42 FUJIFILM CORPORATION: COMPANY SNAPSHOT (2022) 289
14.1.8 GENSCRIPT BIOTECH CORPORATION 292
TABLE 355 GENSCRIPT BIOTECH CORPORATION: BUSINESS OVERVIEW 292
FIGURE 43 GENSCRIPT BIOTECH CORPORATION: COMPANY SNAPSHOT (2021) 293
14.1.9 TAKARA BIO INC. 296
TABLE 356 TAKARA BIO INC.: BUSINESS OVERVIEW 296
FIGURE 44 TAKARA BIO INC.: COMPANY SNAPSHOT (2022) 297
14.1.10 OXFORD BIOMEDICA 300
TABLE 357 OXFORD BIOMEDICA: BUSINESS OVERVIEW 300
FIGURE 45 OXFORD BIOMEDICA: COMPANY SNAPSHOT (2022) 301
14.1.11 NOVARTIS AG 303
TABLE 358 NOVARTIS AG: BUSINESS OVERVIEW 303
FIGURE 46 NOVARTIS AG: COMPANY SNAPSHOT (2022) 304
14.1.12 PRECISION BIOSCIENCES 306
TABLE 359 PRECISION BIOSCIENCES: BUSINESS OVERVIEW 306
FIGURE 47 PRECISION BIOSCIENCES: COMPANY SNAPSHOT (2022) 306
14.1.13 BLUEBIRD BIO, INC. 308
TABLE 360 BLUEBIRD BIO, INC.: BUSINESS OVERVIEW 308
FIGURE 48 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT (2022) 308
14.1.14 SARTORIUS AG 310
TABLE 361 SARTORIUS AG: BUSINESS OVERVIEW 310
FIGURE 49 SARTORIUS AG: COMPANY SNAPSHOT (2022) 311
14.1.15 DANAHER CORPORATION 313
TABLE 362 DANAHER CORPORATION: BUSINESS OVERVIEW 313
FIGURE 50 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 314
14.1.16 SIRION BIOTECH 317
TABLE 363 SIRION BIOTECH: BUSINESS OVERVIEW 317
14.2 OTHER PLAYERS 319
14.2.1 VGXI, INC. 319
14.2.2 WAISMAN BIOMANUFACTURING 320
14.2.3 KANEKA EUROGENTEC S.A. 321
14.2.4 PLASMIDFACTORY GMBH 321
14.2.5 ATUM 322
14.2.6 ADDGENE 322
14.2.7 CELL AND GENE THERAPY CATAPULT 323
14.2.8 BATAVIA BIOSCIENCES B.V. 323
14.2.9 ALTOGEN BIOSYSTEMS 324
*Details on Business Overview, Products & services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
15 APPENDIX 325
15.1 DISCUSSION GUIDE 325
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 329
15.3 CUSTOMIZATION OPTIONS 331
15.4 RELATED REPORTS 331
15.5 AUTHOR DETAILS 332